



INVESTMENT ON CLINICAL VALIDATION STUDIES

KEY ELEMENTS AND ELIGIBILITY CRITERIA

The Paris Institute of Translational Neuroscience (IHU-A-ICM) has funded since 2017, projects dedicated to clinical proofs-of-concept in:

- innovative **medical technologies**
- drugs / compounds **repositioning**

This call for proposals is open to everyone working in the IHU perimeter.

NEUROCATALYST will award up to **150 000 Euros** per project (After a go/no go phase to validate feasibility) and provide a dedicated project manager to develop the study.

SELECTION CRITERIA

An evaluation committee composed of intern and extern medical experts and specialists of intellectual property will review the projects according to 3 criteria:

1. Capacity to generate strong **intellectual property** and allowing to pursue with a complete development program, and/or capacity to demonstrate a **medico economical utility**;
2. Scientific quality and capacity to address an **unmet medical need**;
3. Technical, methodological and regulatory **feasibility**, power of efficacy markers and their capacity to have early read-outs.

APPLICATION FORM CONTENT, CALENDAR

The application form is available on the website: <https://www.icm-institute.org/neurocatalyst>

It includes:

- Study synopsis
- Project leaders
- Scientific and medical rationale, competitive approaches
- Research and tech transfer (intellectual property or medico-economical utility)
- Budget and milestones

The project may be submitted in French or in English.

Submission deadline **15 May 2018** - Results **30 June 2018**

neurocatalyst@icm-institute.org